Polymyositis Initiation Involving Amlodipine Besylate
R. M. Golding1, L. G.F. Giles2 & E. M. Sokoya3 Show affiliations
- The University of New South Wales, Australia
- University of North Queensland, Australia
- Baylor College of Medicine, United States
American Journal of Immunology, Volume 2, Issue 1, pp. 19–22 · doi.org/10.3844/ajisp.2006.19.22
Abstract
Based on extensive blood pressure data and results from a scientific model of the analysis of the rate processes involved in polymyositis the evidence suggests that the polymyositis in a particular patient was initiated by taking the drug amlodipine besylate (norvasc). The method of our analysis should serve as a foundation in handling other drug related interactions.
Licence and reuse
Free to read. This article carries the publisher’s copyright, as printed on it: © 2006 Science Publications. It is free to read; ask us before reusing it.
How to reuse this articleResponses (0)
About this article
Golding, R. M., Giles, L. G. & Sokoya, E. M. (2006). Polymyositis Initiation Involving Amlodipine Besylate. American Journal of Immunology, 2(1), 19–22. https://doi.org/10.3844/ajisp.2006.19.22
- Licence
- © Science Publications
- Issue
- Volume 2, Issue 1
- Policies
- Editorial independenceUse of generative AIData availabilityAppeals and complaints
- Version
- Version of record